COMMUNIQUÉS West-GlobeNewswire

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
12/05/2025
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Akoya Biosciences Reports First Quarter 2025 Financial Results
12/05/2025
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2025. “ [...]
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy [...]
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/05/2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option [...]
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 [...]
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
12/05/2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular [...]
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
12/05/2025
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that [...]
Stereotaxis Reports 2025 First Quarter Financial Results
12/05/2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first [...]
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 [...]
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to [...]
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
12/05/2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 [...]
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
12/05/2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and [...]
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder [...]
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
12/05/2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
IBA – ACQUISITION OF OWN SHARES
12/05/2025
Immediate Release – May 12 th , 2025 Louvain-la-Neuve, Belgium, May 12 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam [...]
IBA – ACQUISITION D’ACTIONS PROPRES
12/05/2025
Publication immédiate – 12 mai 2025 Louvain-la-Neuve, Belgique, 12 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
Fagron shareholders approve all voting items AGM
12/05/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its [...]

Pages